Oesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation
British Journal of Surgery · 2024
DOI: 10.1093/bjs/znae117 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Siobhan Chien und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Cancer Sciences, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Barrett Esophagus, Esophagoscopy, Esophageal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Barrett's oesophagus surveillance places significant burden on endoscopy services yet is vital to detect early cancerous change. Oesophageal cell collection device (OCCD) testing was introduced across Scotland for Barrett's surveillance in response to the COVID-19 pandemic. This national pragmatic retrospective study presents the CytoSCOT programme results and evaluates whether OCCD testing is successfully identifying high-risk Barrett's patients requiring urgent endoscopy.
Methods
All patients undergoing OCCD testing for Barrett's surveillance across 11 Scottish health boards over a 32-month period were identified. Patients who underwent endoscopy within 12 months of OCCD test were included. Individual patient records were interrogated to record clinical information and OCCD test result to categorize patients into risk groups. Endoscopic histopathology results were analysed according to risk group and segment length. Patients were deemed high risk if the OCCD test demonstrated atypia and/or p53 positivity.
Results
4204 OCCD tests were performed in 3745 patients: 608 patients underwent endoscopy within 12 months and were included in this analysis. Patients with longer Barrett's segments were significantly more likely to have an abnormal OCCD test. 50/608 patients (8.2%) had high-grade dysplasia or cancer on endoscopic biopsies: this equates to 1.3% of the total group (50/3745). 46/50 patients (92.0%) were deemed high risk, triggering urgent endoscopy: this rose to 100% with insufficient tests removed. There were no cancers diagnosed within 12 months post-OCCD in the low-risk group.
Conclusion
OCCD testing is an effective triage tool to identify high-risk patients with Barrett's oesophagus requiring further investigation with endoscopy within the real-world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Cancer Sciences, University of Glasgow, Glasgow, UK.
- Centre for Sustainable Delivery, Golden Jubilee National Hospital, Glasgow, UK.
- Department of General Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
- Centre for Liver & Digestive Disorders, Royal Infirmary of Edinburgh, Edinburgh, UK.
- Department of General Surgery, Victoria Hospital, Kirkcaldy, UK.
- Department of General Surgery, University Hospital Wishaw, Wishaw, UK.
ORCID-Profile: Siobhan Chien
Zitieren
APA
Chien, S., Glen, P., Penman, I., Cruickshank, N., Bryce, G., Crumley, A., Phull, P., Miller, M., Fletcher, J., Gunjaca, I., Apollos, J., Robertson, K., & Fullarton, G. (2024). Oesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation. British Journal of Surgery. https://doi.org/10.1093/bjs/znae117
Vancouver
Chien S, Glen P, Penman I, Cruickshank N, Bryce G, Crumley A, et al. Oesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation. British Journal of Surgery. 2024. doi:10.1093/bjs/znae117
BibTeX
@article{Chien2024,
author = {Chien, Siobhan and Glen, Paul and Penman, Ian and Cruickshank, Neil and Bryce, Gavin and Crumley, Andrew and Phull, Perminder and Miller, Michael and Fletcher, Jonathan and Gunjaca, Ivan and Apollos, Jeyakumar and Robertson, Kevin and Fullarton, Grant},
title = {Oesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation},
journal = {British Journal of Surgery},
year = {2024},
doi = {10.1093/bjs/znae117}
}
EUVIMED